

# INDEX

- 17-allylaminogeldanamycin (17-AAG), 197
- 14-3-3 antagonists, 177
- $\alpha$ -1 antitrypsin, 95
- $\alpha$ -1-antichymotrypsin, 120
- $\alpha$ -1 acid glycoprotein, 95
- $\alpha$ -cyano-4-hydroxycinnamic acid, 98
- $\alpha$ -2 macroglobulin, 95, 120
- Ab initio* folding simulations, 266
- Acrylamide, 43
- Acute myelogenous leukemia (AML), 281, 282
- Acute lymphocytic leukaemia (ALL), 281, 282
- Adenomatous polyps, 332
- Adenocarcinoma
  - Pancreatic 62
  - Lung 94
- Adhesive domains, 146
- Adivin affinity chromatography, 289
- Adjuvant systematic therapy, 215
- African-American, 337, 338
- Affinity
  - Chromatography, 24, 47, 289
  - Column, 53
  - Ligand, 26
  - Metal, 22
  - Proton, 38
  - Reagents, 75
  - Surface 23
- Aha1 protein, 197
- $\alpha$ -helices, 210
- AIF (apoptosis-inducing factor), 208
- Algorithms
  - Artificial neural network 29
  - Search 63
- Alkylation, 44
- Alzheimer's, 101
- Allele discrimination, 223
- Allele frequencies, 223
- American Cancer Society (ACS), 333
- Ammonium sulfate, 209
- Androgen responsive elements (AREI, II), 174
- Androgen receptor (AR), 169
- Anion-exchange, 22
- Antibodies
  - Biotinylated, 67
  - Immobilized, 70
  - Monoclonal, 66

- Anthracycline, 280  
 Anthropology, 328  
 APC, 323  
 Apolipoprotein, 27  
 Apolipoprotein E (ApoE), 152  
 Apoptosis, 3, 11, 177, 178  
 Apoptotic-protease-activating factor 1 (Apaf-1), 205  
 Apoptosis signal-regulating kinase 1 (ASK1), 177  
 AQUA, 83  
 Archetypal yeast Gal4p, 254  
 Array formats, 7  
 Array-based comparative genomic hybridization (aCGH), 276  
 Arthritis, 164  
 Aspartic acid, 164  
 ATM-*p53* pathway, 178  
 Atomic Force Microscopy (AFM), 71  
 ATP binding pocket, 193  
 ATPases, 138  
 Autosomal, 139  
 Axillary lymph nodes, 275  
  
 $\beta$ -Amyloid, 101, 172  
 14-3-3/BAD, 180, 181  
 Bacterial artificial chromosome (BAC) clones, 281  
 BAD/Bcl-X<sub>i</sub> complex, 180  
 BAG-1, 207  
*Bax*, 177  
 Bcl-homology 3 (BH3), 180  
 Base-induced elimination, 289  
 Benign prostate hyperplasia (BPH), 96  
 Binding Cleft, 203  
 Binary physical interactions, 259  
 Biobanks, 326, 327  
 Bioinformatics, 27  
 Biomarkers for ovarian cancer, 134  
 Biomolecular interaction Network Database (BIND), 267, 268  
 Biosensors, 69  
 Biotinylated, 48  
 Blood products, 325, 327 (*BRCA1*, 2), 137, 140, 336  
 BRC repeats, 137  
 Bradykinin, 165  
 British Human Genetics Commission, 331  
  
 Ca<sup>2+</sup>-binding EF-hand motif, 209  
 (CA-125II, CA 15-3, CA72-4), 144, 149  
*Caenorhabditis elegans*, 256, 267  
 Calmodulin, 68, 209  
 Calmodulin binding peptide tag, 258  
 Calcium binding proteins, 209  
 Calvasculin, 212  
 Cancer Biomarkers, 2  
     New approach to discovery, 6  
     Phases of development, 4  
     Promising sources for discovery, 10  
 Capillary zone electrophoresis (CZE), 87  
 Carbodiimide condensation, 288  
 Carcinoma  
     Breast, 59  
     Colon, 75  
     Colorectal, 59  
     Heptocellular, 94  
     Renal cell, 29  
 Carcinoembryonic antigen, 6,4  
 Carcinoma-associated glycoprotein antigen (CA-125), 4  
 Carcinoma-associated glycoprotein antigen (CA-125), 144  
 Casein kinase II, 212  
 Caspase-dependent pathway, 204, 205  
 Caspase recruitment domain (CARD), 205  
 Catalytic subdomains, 199  
*CDKNA2*, 228  
*Cdc25c*, *Cdc25B*, 179  
 cDNA libraries, 151  
 cDNA microarrays, 260, 261  
*Cellular proliferation*, 353  
 Cellular stimuli, 194  
 Centromeric, 167  
 Centrifugal, 6, 45  
 Cervical cancer, 334  
 Cervical intraepithelial neoplasia (CIN), 334  
 Chaperones, 192, 193  
 Checkpoint kinase 1 (Chk1), 183  
 Chelated metal ions, 68  
 Chemotherapy, 121  
 Chemiluminescence, 75  
 Chemoresistant variants, 201  
 Chromatin condensation, 190  
 Chromatin remodeling, 138  
 Chromatography  
     Ion-exchange, 81  
     Multidimensional, 81

- Size-exclusion, 87
- Two-dimensional, 88
- Chromosomal location, 210
- Chromosomes (1q21, 3f3, 2q34), 212
- Chromosome 19 (19q13.3-q13.4), 164
- Chromosomes 17q, 13q, 137
- Chromosome deletions, 219
- Chromosomal translocation, 228
- Chronic corticosteroid treatment, 335
- Cibacron blue, 24
- Claudin3, 152
- Clinical diagnosis, 5
- Clinical follow-up, 328
- Clustered EST, 349
- Coding exons, 168
- Coevolution, 267
- Colorimetric, 78
- Colonoscopy, 5, 114, 332
- Colonic perforation, 332
- Colorectal cancer, 4, 332
- Colorectal Carcinoma, 179
- Collision-induced dissociation (CID), 91, 92
- Commercial Biobanks, 13
- Comparative hybridization, 223
- Contralateral tumours, 276
- Corpus callosum, 100
- Correlated mutations, 263
- Correlated mRNA expression (synexpression), 262
- CpG islands, 224
- CpG methylation, 224
- c-RAF kinase, 178, 179
- Cryogenic, 103
- Crystallin proteins, 198
- CT colography (virtual colonoscopy), 332
- CT scanners, 333
- Cyclin D1, 277
- Cyclin-dependent kinase (Cdc25), 179
- Cytoplasmic, 179
- Cytochrome c, 180, 181
- Cystadenocarcinoma, 143
- Cytoreductive surgery, 145
- Cytokines 45
- Cysteine proteases, 199
- 2-D liquid chromatography, 88, 89
- 2-D PAG electrophoresis, 42, 43
- Database of interacting proteins (DIP), 268
- Database of predicted functional associations among genes/proteins (STRING), 268
- Deleterious mutation, 141
- Diethylstilbestrol (DES), 335
- Differential methylation hybridization (DMH), 222
- Differential gene expression, 274
- Digital rectal examination (DRE), 116, 333
- DIGE, 49, 51
- Distant metastasis, 215
- Dizygotic, 128
- DNA-Activation domain (AD), 254
- DNA-binding domain (DB), 254
- DNA methylation, 15, 218, 352
- DNA methyltransferases (DNMTs), 224
- DNA microarrays, 16
- DNA repair, 137
- DNA samples, 327
- Drosophila melanogaster*, 27
- Ductal carcinoma *in situ* (DCIS), 276
- E-cadherin, 212
- E. coli*, 264
- EDRN, 148
- Electron capture dissociation, (ECD), 289
- Electrolyser, 46
- ELISA, 72
- ELM database, 286
- EMSY protein, 137, 140
- Embryonic, 164
- Endometrial carcinoma, 143
- Endometriosis, 143
- Enrichment, 24, 45, 287
- Epidemiology, 328
- Epigenetic, 223, 224
- Epigenetic events, 277
- Epitopes, 73
- Estrogens, 169
- Estrogen-responsive finger protein (Efp), 186
- Ethane-1,2-dithiol, 289
- Ethical committees/organizations, 323
- Ethical concerns, 321
- Ethical framework, 328
- Ethical issues in biobanking, 328
- Ethnic groups, 338
- European Agency for the Evaluation of Medicinal Products (EMA), 16

- European Community, 325  
 European National Ethics Committees, 328  
 Evolutionary divergence, 269  
 Exogenous signals, 191
- Familial adenomatous polyposis (FAP), 322  
 Fanconi Anemia, 139  
 False-positives/ negatives, 262, 289  
*Fas ligand* gene, 182  
 Fecal immunochemical test (FIT), 333  
 Fecal occult blood test (FOBT), 333  
 Fibroblast-specific protein (FSP10), 212  
 Finasteride, 122  
 Flexible sigmoidoscopy, 333  
 Fluorescence probes, 221  
 Fluorescent-based PCR, 221  
 Fluorophores, 73, 74  
 Fluorescent protein  
   cyan (CFP), 74  
   green (GFP), 74  
   yellow (YFP), 74  
 Fluorescent signals, 261  
 Follicular lymphoma, 279  
 Food and Drug Administration (FDA), 16  
 Forkhead transcription factors (FKHLRs), 177, 182  
 Formalin-fixed tissues, 221  
 FRET, 73
- G0/G1, G1/S, G2/M transitions, 182  
 Gas-phase  $\beta$  elimination, 289  
 Gel-based MSP, 220  
 Gemcitabine, 63  
 Gene expression patterns, 351  
 Gene locus, gene organization, 167  
 Gene Microarray Pathway Profiler (GenMAPP), 14  
 Gene Ontology (GO), 270  
 Gene signatures, 275  
 Gene-specific tags, 175  
 Genetic susceptibility, 331  
 Genetic testing, 335  
 Genotoxic, 186  
 General Repository for Interaction Datasets (GRID), 267  
 Germline mutations, 135, 142  
 Glandular kallikrein, 165
- Gleason  
   score, 121  
   grade 118  
 Glutathione S-transferase, 77  
 Glucocorticoid receptor, 197  
 Glucocorticoid receptor complexes, 213  
 Glucose related protein 94 (GRP94), 193  
 Glycocapture, 95  
 Glycolysation 86  
 glycosylphosphoinositol-linked glycoprotein, 143  
 Group stigmatization, 338  
*GSTP1*, 128, 134  
 GST-SH2, 296
- Haptoglobin, 95  
 Heat shock proteins (HSPs), 190  
 Heavy chain IIA non-muscle myosin, 212  
 Heavy metals, 190  
 Helical computed tomography, 333  
*Helicobacter pylori*, 257, 267  
 Hemo-pexin, 95  
 Hepsin, 134  
 Hepatocyte growth factor, 207  
 Heptaglobin-  $\alpha$ -subunit, 151  
 Heptacellular Carcino, 94  
 Hepatocytes, 94  
 HER-2/neu, 216  
 Hereditary, 128, 131  
 Heredity non-polyposis colon cancer (HNPCC), 322  
 Heredity breast and ovarian cancer (HBOC), 336  
 Heterozygosity, 11, 352  
 Heuristic reliability factors, 272  
 High-grade squamous intraepithelial lesions (HSILs), 353  
 Hippocampus, 168  
 Histone deacetylation, 225  
 Histopathologic variables, 276  
*HIS3* gene, 257  
 Homoarginine, 38  
 Horseradish peroxidase, 73  
 Homeostasis, 177  
*Homo sapiens*, 256  
 Hormone therapy, 216  
 Hormonal ablation, 121  
 Host immune system, 45

- HPV DNA testing, 335  
HSP90 $\alpha$ , HSP90 $\beta$ , 192  
HSP70, 202  
HSP27, 198  
Human Genome Diversity project, 330  
Human Genome Organization (HUGO), 328  
Human ovarian surface epithelial (HOSE), 153  
Human papillomavirus (HPV), 334  
Human protein interactome, 267  
Human orthologs, 267, 268  
Human tissue kalikreins (hK, *KLK*), 164  
Hydrophobicity 87  
Hybrid  
    Mass spectrometers, 99  
    Analyzer, 92  
Hypermethylation, 217  
  
ICAT, 94, 288  
ICP-MS, 295  
Imaging MS, 61  
Immunoassays, 63, 122  
Immunoblotting, 76  
Immunocompromised, 335  
Immunohistochemical, 132  
Immunoprecipitation, 75  
Immunoreactive, 120, 185  
Immune response, 281  
Immunologic therapy, 279  
Immunoglobulin (IgG)-binding domains, 258  
Inflammatory cascades, 171  
Informed consent, 329  
*In silico* comparison, 260  
*In silico* Y2H, 265  
*In situ* hybridization, 171, 353  
Insulin-like growth factor 1 (IGF-1), 179  
Insulin receptor substrate-1 (IRS-1), 179  
Interleukin-3, 180  
Intron, 168  
Interologs, 267  
Integral membrane proteins, 257  
Intractome, 249, 267  
Iodoacetamide 43  
Ion suppression, 293  
IPG, 47  
Isoforms, 86  
Isoforms [ $\beta$ ,  $\gamma$ ,  $\epsilon$ ,  $\eta$ ,  $\sigma$ ,  $\tau$  ( $\theta$ ), and  $\zeta$ ], 177  
  
Isotope-coded glycosylation-site-specific-tagging (IGOT), 9  
Isotope-coded tagging, 9  
  
JNK-SAPK (JUN N-terminal kinase-stress-activated protein kinase), 208  
  
Kallekrein gene expression, 167, 168  
Kallekrein transcriptome, 176  
Kinin, 165  
Kyoto Encyclopedia of Genes and Genomes (KEGG), 14  
  
Label-free, 75  
Labelling  
    ICAT, 94  
    *In vivo*, 86  
    Limitations 96  
    MCAT, 84  
    Preferential 75  
    Post-digestion, 86  
    Radioisotope, 51  
    Specific antibodies, 60  
    SILAC, 52  
Large-B-cell lymphoma, 279  
Large cell lung carcinoma (LC), 227, 228  
Laser capture microdissection (LCM), 53  
Laser light-induced fluorescence endoscopy (LIFE) 227  
Lewis X mucin determinant (OVX1), 149  
LexA-VP16 transcription factor, 257  
Liquid-based cytology, 335  
Lipopolysaccharide, 131  
Lipoproteins, 131, 257  
LnCAP cell line, 79  
Lower limit for normal (UNL), 124  
Luminescence-based mammalian interactome mapping(LUMIER), 272  
Lung adenocarcinoma, 282  
Lymphocytic leukaemia, 281  
Lymph-node metastasis, 277  
Lymph-node positive, 278  
Lysyl-bradikinin (kallidin), 171  
Lysate arrays, 78  
  
Macrophage, 149  
Macrophage colony stimulating factor (M-CSF), 149

- Magnetic  
 Analyzer, 96  
 Beads, 26  
 Field, 92  
 Resonance imaging, 102  
 Resonance spectroscopy, 102
- Mammography, 114, 184
- MasCot, 93
- Matrix metalloproteinases, 230
- MCF-7 cell line, 201
- Medical confidentiality, 331
- Medical research Council (MCR), 324
- Membrane-associated adhesive glycoprotein  
 CD44, 212
- Methylation, 118, 130
- Methylation specific PCR (MSP), 220
- Methylation specific primers, 220
- MethylLight, 232
- Metal affinity chromatography (IMAC),  
 288
- MFA1pr-HIS3*, 263
- Microchannel plates, 103
- Microsatellite instability, 223, 352
- Mitochondrial DNA mutations 10
- Mitogen-activated protein kinase kinase  
 1 (MEKK1), 177
- Mitogenic signalling, 178
- Mitogen-activated protein kinases  
 (MAPKs), 296
- Mitotic index, 277
- Mobility  
 electrophoretic, 49  
 Ion, 86
- Molecular biomarkers, 352
- Molecular Interaction Database (MINT),  
 268
- Molecular predictor, 281
- Monozygotic, 128
- Morphological appearance, 281
- MRM, 92
- mRNA transcripts, 146
- MS detection, 289
- MudPIT, 92
- Multidimensional chromatography, 81, 89,  
 94
- Multidomain protein, 264
- Multidrug resistance, 201
- Multiple myeloma, 113
- multivariate, 149
- Multiple sequence alignments (MSAs), 266
- Mus musculus* (mouse), 275
- Myriad prinet database, 253
- Myelin basic protein, 102
- 2-nitrobenzenesulfonyl chloride, 83
- National Bioethic Advisory Commission,  
 324
- National repositories, 326
- NCI-60 cell lines, 77
- Necrosis factor- $\alpha$ , 182
- Nested MSP, 232
- Neurodegenerative, 164
- Neu oncogene, 185
- Nitrocellulose, 66
- Node-negative breast cancer, 215
- Normal ovarian epithelial (NOE), 171
- Nucleoprotein filament, 138
- Nuffield Council on Bioethics, 324
- Oligonucleotides microarrays, 261
- Oncology trials, 340
- Oncomine database, 274
- On column desalting, 293
- Oncogenes, 134
- On-line Mendelian Inheritance in Man  
 (OMIM), 272
- Open reading frames (ORFs), 251, 349
- Orbitrap, 92
- Organization for Economic Co-Operation  
 and Development (OECD), 328
- Organelle swelling, 191
- Orthologs, 267
- Osteopontin, 145
- Ovarian cancer, 134, 136, 137
- OVCA 433 cell line, 143
- Overall survival (OS), 207
- OVCAR-3 cell line, 171
- $\pi$ -class *GST*, 128
- P53* gene, 140
- (*p21<sup>CIP1/WAF1</sup>*, *p16<sup>INK4a</sup>*), 215
- <sup>32</sup>P labelling, 295
- Paclitaxel, 102
- Pair-wise protein interactions, 256
- Paired box gene 5 (*PAX5*), 228
- Pancreatic/renal kallikrein, 166
- Pap smears, 334
- PCR, 64

- Peak capacity, 88
- Peak parking, 293
- Penetrance, 141
- Peptide mass finger printing (PMF), 289
- Peptide backbone, 291
- Peroxiredoxin I, 62
- Phosphate esters, 295
- Phospholipids-binding proteins, 253
- Phosphoprotein affinity tagging, 288
- Phosphoserine, 288
- Phosphotyrosine, 292
- Phosphorylation, 15
- Phosphatidylinositol-3 kinases (PI3Ks), 11, 296, 299, 302
- Phosphatidylinositol-3, 4, 5-triphosphate (PIP<sub>3</sub>), 11, 299
- Phosphorylation, 38, 78
- Phosphorylated Akt, 131, 298, 300
- Phosphatases, 183
- Physical and functional interactions, 259
- Placebo, 117
- Plasminogen, 148
- Prefractionation, 24, 88
- Photocleavable, 94
- Phylogenetic profiles, 264
- Polymerase chain reaction (PCR), 6, 220, 221
- Polyvinylidene difluoride membrane, 296
- Poly-L-lysine, 67
- Polymorphism, 133
- Population-based screening, 134, 331, 332
- Portability and Accountability Act (HIPAA), 331
- Post-translational modifications, 79, 80
- Postoperative, 127
- Precursor ion/neutral loss scans, 292, 91
- Premenopausal, 143
- Preoperative, 127
- Preys, 272
- Privacy, 331, 339
- Probe hybridization, 220, 221
- Pro-caspase-9, 204
- Proenzyme, 122
- Promoter hypermethylation, 220
- Promoter region, 220
- Prostate cancer, 333
- Prostasin, 148
- Prostate intraepithelial neoplasia (PIN), 132
- Prostatectomy, 132
- Prostate-specific antigen (PSA), 115
- Prostatic acid phosphatase (PAP), 114
- PSA
  - Isoforms, 122
  - precursor (pPSA), 122
  - threshold, 116
  - Specificity, 15
  - complexed (cPSA), 120
  - total (tPSA), 123
  - density, 125
  - velocity, 123
- Proteomic
  - platforms, 21
  - profiling, 39, 41
  - patterns, 42
  - expression, 43, 50
  - analysis, 54
- Protein Microarrays
  - analytical, 63, 66
  - functional, 76
- Protein function annotation, 274
- Protein phosphorylation, 56, 250
- Protein-protein interaction networks, 250
- Protein family 14-3-3, 177
- Protein kinase C, 172
- Protein translocation, 190
- Proteolytic cascades, 170
- Proteolytic machinery, 169
- PtdIns(4,5) (PIP<sub>2</sub>), 297, 298
- Purine analogues, 280
- PVDF, 66
  
- Ras-Raf, 186
- Radiation therapy, 202
- Radioactively labelled, 220
- Radiotherapy, 121
- Radioimmunoassay, 143
- Radioimmunometric assay, 143
- Randomized trials, 154 (Rad24, Rad25), 183
- RAD51, 137
- RAS, 296
- Reactive oxygen species, 199
- Receiver operating curve (ROC), 3
- Receptor tyrosine kinases (RTKs), 296
- RECIST Group, 145
- Reductive alkylation, 289
- Regulatory Issues, 321, 340
- Remote imaging, 224

- Renal cell carcinoma (RCC), 201  
*Renilla* luciferase enzyme (RL), 272  
 Research protocols, 324  
 Restriction landmark genomic screening (RLGS), 220  
 Receptor tyrosine kinases (RTKs), 296  
*RNASEL*, 129  
 RNA polymerase II, 275  
 Rodent orthologs, 172  
  
 (S100), 209, 210  
 S100A4/annexin II complex, 218  
 SAGE, 254, 151  
 Salivary gland, 168  
 Sandwich assay, 75  
 Scaffolding protein, 199  
 Scoring algorithms, 289  
 Screening strategies, 154  
*Schizosaccharomyces pombe*, 183  
 Secondary uses, 328  
 Secretory, 122  
 Selenium, 131  
 Seminal plasma, 170  
 SELDI, 2, 21  
 SEQUEST, 93  
 Serine proteases, 176  
 Similarity of phylogenetic trees (mirrortree), 264  
 Sigmoidoscopy, 5  
 Single nucleotide polymorphism (SNP), 6, 172  
 Signal transduction, 79  
 SILAC, 82  
 Silane, 67  
 Sinapinic acid, 98  
 Small cell lung Carcinoma (SCLC)/ non-SCLC (NSCLC), 227  
 Small integrin binding proteins, 145  
 Somatic, 129  
 Somatic mutations, 278  
 Space-charge, 91  
 Speciation, 269  
 Spiral computed tomography (CT), 227  
 Splice variants, 261  
 Sporulation, 262  
 Squamous cell carcinoma (SCC), 228  
 Sporadic ovarian cancer, 140  
 SRC tyrosine kinase, 196  
 Stacked sorbents, 26  
  
 Staurosporin, 204  
 stathmin (oncoprotein 18), 63  
 Steric hindrance, 205  
 Streptavidin, 67  
 Stabilizing ring-ring, 183  
 Stop codon, 168  
 Stratum corneum, 170  
 Stratifin (14-3-3 $\sigma$ ), 184  
 Stress sensors, 208  
 Stem-cell transplantation, 279  
 Stoichiometry, 287  
 Streptavidin-phycoerythrin, 261  
 Strong cation exchange (SCX), 288  
 Stored Human biological materials, 327  
 Stool DNA testing, 333  
 Surface plasmon resonance, 69  
 Susceptibility genes, 128  
 Surveillance, Epidemiology and End Results (SEER), 153  
 Suppressor genes, 155  
 Substrate-binding domain, 206  
 Survivin, 216  
 Supervised learning, 277  
 Susceptibility genes, 276  
 Synthetic lethality, 258  
 Synthetic lethal analysis, 262  
 Synthetic genetic array (SGA) analysis, 262  
 Systems biology, 249  
 Symptom questionnaire, 332  
  
 Tagged multiprotein complexes, 253  
 Tandem affinity purification (TAP)/MS, 258  
 Taqman probe, 222  
 Telomere, 167  
 Testisin, 148  
 Testicular acid phosphate (*ACPT*), 167  
 Tetratricopeptide-containing repeats (TPR), 203  
 Thermotolerant, 200  
 Thiourea, 43  
 Thioacetylated, 9  
 Tissue-type plasminogen activator (t-PA), 218  
 Tobacco etch virus, TEV, 258  
 Topoisomerase II enzymes, 201  
*TP53* mutations, 195  
 Transcription factors, 6  
 Transferrin, 24

- Transthyretin, 35
- Transabdomal ultrasonography, 135
- Transrectal ultrasound, 125, 126
- Transvaginal sonography (TVS), 144
- Trans-membrane receptors, 185
- Transmembrane glycoproteins, 212
- Transcriptional regulator  $\Delta$ Np63, 185
- Transacting transcription, 172
- Trichostatin-A, 63
- Tryptophan, 83
- Trypsin, 39
- Tumour necrosis factor receptor associated protein1 (TRAP1), 193
- Tumour necrosis factor (TNF)- $\alpha$ , 273
- Tyrosine phosphorylation, 12, 59
- Tyrosine kinase Wee1, 179
  
- Ultrafiltration, 93
- UNESCO, 323
- Upstream DNA sequences (UAS), 254
  
- Uracil, 220
- US Public Health Service (USPHS), 335
  
- VICAT, 83
- Vinylpyridine, 43
- Visible-coded affinity tag (VICAT), 9
- Vitamin E, 131
  
- Western blot, 9
- White-light bronchoscopy, 227
- World Health organization (WHO), 5, 328
- World Medical association, 323
  
- X-ray imaging, 227
  
- YAG laser, 101
- Yeast two hybrid (Y2H) system, 254
- YKL-40, 150
  
- Zinc finger protein, A20, 181
- Zymogen activation, 171

